Literature DB >> 32088984

Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program.

W H Wilson Tang1,2, Jennifer D Wilcox2, Miriam S Jacob1, Erika B Rosenzweig3, Barry A Borlaug4, Robert P Frantz4, Paul M Hassoun5, Anna R Hemnes6, Nicholas S Hill7, Evelyn M Horn8, Harsimran S Singh8, David M Systrom9, Ryan J Tedford10, Rebecca R Vanderpool11,12, Aaron B Waxman9, Lei Xiao13, Jane A Leopold14, Franz P Rischard15.   

Abstract

BACKGROUND: Invasive hemodynamic evaluation through right heart catheterization plays an essential role in the diagnosis, categorization, and risk stratification of patients with pulmonary hypertension.
METHODS: Subjects enrolled in the PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) program undergo an extensive invasive hemodynamic evaluation that includes repeated measurements at rest and during several provocative physiological challenges. It is a National Institutes of Health/National Heart, Lung, and Blood Institute initiative to reclassify pulmonary hypertension groups based on clustered phenotypic and phenomic characteristics. At a subset of centers, participants also undergo an invasive cardiopulmonary exercise test to assess changes in hemodynamics and gas exchange during exercise.
CONCLUSIONS: When coupled with other physiological testing and blood -omic analyses involved in the PVDOMICS study, the comprehensive right heart catheterization protocol described here holds promise to clarify the diagnosis and clustering of pulmonary hypertension patients into cohorts beyond the traditional 5 World Symposium on Pulmonary Hypertension groups. This article will describe the methods applied for invasive hemodynamic characterization in the PVDOMICS program. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02980887.

Entities:  

Keywords:  exercise test; hemodynamics; phenomics; pulmonary hypertension; vascular diseases

Mesh:

Substances:

Year:  2020        PMID: 32088984      PMCID: PMC7046052          DOI: 10.1161/CIRCHEARTFAILURE.119.006363

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  23 in total

Review 1.  Impact of integrative cardiopulmonary exercise testing on clinical decision making.

Authors:  D Y Sue; K Wasserman
Journal:  Chest       Date:  1991-04       Impact factor: 9.410

2.  Zero reference level for right heart catheterisation.

Authors:  Gabor Kovacs; Alexander Avian; Andrea Olschewski; Horst Olschewski
Journal:  Eur Respir J       Date:  2013-06-21       Impact factor: 16.671

3.  The invasive cardiopulmonary exercise test.

Authors:  Bradley A Maron; Barbara A Cockrill; Aaron B Waxman; David M Systrom
Journal:  Circulation       Date:  2013-03-12       Impact factor: 29.690

4.  Differential hemodynamic effects of exercise and volume expansion in people with and without heart failure.

Authors:  Mads J Andersen; Thomas P Olson; Vojtech Melenovsky; Garvan C Kane; Barry A Borlaug
Journal:  Circ Heart Fail       Date:  2014-10-23       Impact factor: 8.790

5.  Simplified calculation of body-surface area.

Authors:  R D Mosteller
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

6.  Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Rick A Nishimura; Paul Sorajja; Carolyn S P Lam; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2010-06-11       Impact factor: 8.790

7.  Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2018-05-23       Impact factor: 12.035

8.  Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes.

Authors:  Gregory D Lewis; Ryan M Murphy; Ravi V Shah; Paul P Pappagianopoulos; Rajeev Malhotra; Kenneth D Bloch; David M Systrom; Marc J Semigran
Journal:  Circ Heart Fail       Date:  2011-02-03       Impact factor: 8.790

9.  Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology.

Authors:  R A Krasuski; J J Warner; A Wang; J K Harrison; V F Tapson; T M Bashore
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

10.  Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.

Authors:  Tufik R Assad; Bradley A Maron; Ivan M Robbins; Meng Xu; Shi Huang; Frank E Harrell; Eric H Farber-Eger; Quinn S Wells; Gaurav Choudhary; Anna R Hemnes; Evan L Brittain
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

View more
  6 in total

1.  The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension.

Authors:  Rebecca R Vanderpool; Kendall S Hunter; Michael Insel; Joe G N Garcia; Edward J Bedrick; Ryan J Tedford; Franz P Rischard
Journal:  Chest       Date:  2021-10-09       Impact factor: 10.262

2.  Invasive Hemodynamic and Metabolic Evaluation of HFpEF.

Authors:  J Emanuel Finet; Erik H Van Iterson; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-03-26

Review 3.  NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review.

Authors:  William M Oldham; Anna R Hemnes; Micheala A Aldred; John Barnard; Evan L Brittain; Stephen Y Chan; Feixiong Cheng; Michael H Cho; Ankit A Desai; Joe G N Garcia; Mark W Geraci; Susan D Ghiassian; Kathryn T Hall; Evelyn M Horn; Mohit Jain; Rachel S Kelly; Jane A Leopold; Sara Lindstrom; Brian D Modena; William C Nichols; Christopher J Rhodes; Wei Sun; Andrew J Sweatt; Rebecca R Vanderpool; Martin R Wilkins; Beth Wilmot; Roham T Zamanian; Joshua P Fessel; Neil R Aggarwal; Joseph Loscalzo; Lei Xiao
Journal:  J Am Coll Cardiol       Date:  2021-04-27       Impact factor: 27.203

4.  Microenvironmental Regulation of Macrophage Transcriptomic and Metabolomic Profiles in Pulmonary Hypertension.

Authors:  Min Li; Suzette Riddle; Sushil Kumar; Joanna Poczobutt; B Alexandre McKeon; Maria G Frid; Maureen Ostaff; Julie A Reisz; Travis Nemkov; Mehdi A Fini; Aya Laux; Cheng-Jun Hu; Karim C El Kasmi; Angelo D'Alessandro; R Dale Brown; Hui Zhang; Kurt R Stenmark
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

Review 5.  Exercise metabolomics in pulmonary arterial hypertension: Where pulmonary vascular metabolism meets exercise physiology.

Authors:  Michael H Lee; Thaís C F Menezes; Julie A Reisz; Eloara V M Ferreira; Brian B Graham; Rudolf K F Oliveira
Journal:  Front Physiol       Date:  2022-09-12       Impact factor: 4.755

6.  Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience.

Authors:  Christine L Jellis; Margaret M Park; Aiden Abidov; Barry A Borlaug; Evan L Brittain; Robert Frantz; Paul M Hassoun; Evelyn M Horn; Wael A Jaber; Kim Jiwon; Maria G Karas; Deborah Kwon; Jane A Leopold; Bradley Maron; Stephen C Mathai; Reena Mehra; Franz Rischard; Erika B Rosenzweig; W H Wilson Tang; Rebecca Vanderpool; James D Thomas
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 9.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.